Adia Med Inc. (ADIA)
Stock analysis · OTC · Healthcare · Medical - Pharmaceuticals
Adia Med Inc. (ADIA) is a publicly traded company in the Healthcare sector. Latest price: $0.13. Market cap $11.80M. Trailing PE -0.10. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Proprietary Signals
About Adia Med Inc.
Adia Med Inc. is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, while Adia Labs manufactures and distributes regenerative products. The company is also involved in multiple Institutional Review Board (IRB)-approved clinical studies.
Valuation
| P/E (TTM) | -0.10× |
|---|---|
| P/S (TTM) | 10.83× |
| P/B | -0.03× |
| PEG | 0.00× |
| P/FCF (TTM) | -70.80× |
| EV / EBITDA | -90.13× |
| EV / Sales | 11.63× |
| Earnings Yield | -2253.24% |
| Free Cash Flow Yield | -1.41% |
Fundamentals
| Enterprise Value | $12.67M |
|---|---|
| Revenue (TTM) | $1.09M |
| Net Income (TTM) | -$265.89M |
| Free Cash Flow (TTM) | -$134.49K |
| Net Debt | $865.66K |
| Working Capital | -$714.30K |
| Gross Margin | 46.68% |
| Operating Margin | -20.94% |
| Net Margin | -24.41% |
| Return on Equity | 94.27% |
| Return on Invested Capital | -37.16% |
Peers
Recent News
- Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues
- Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash
- Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position
- Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million
- Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line
Related
Browse more tickers: sitemap